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Abstract
Introduction The precise role of cytomegalovirus (CMV)
infection in contributing to outcomes in critically ill
immunocompetent patients has not been fully defined.
Methods Studies in which critically ill immunocompetent adults
were monitored for CMV infection in the intensive care unit (ICU)
were reviewed.
Results CMV infection occurs in 0 to 36% of critically ill
patients, mostly between 4 and 12 days after ICU admission.
Potential risk factors for CMV infection include sepsis,
requirement of mechanical ventilation, and transfusions.
Prolonged mechanical ventilation (21 to 39 days vs. 13 to 24
days) and duration of ICU stay (33 to 69 days vs. 22 to 48 days)
correlated significantly with a higher risk of CMV infection.
Mortality rates in patients with CMV infection were higher in
some but not all studies. Whether CMV produces febrile
syndrome or end-organ disease directly in these patients is not
known.
Conclusions CMV infection frequently occurs in critically ill
immunocompetent patients and may be associated with poor
outcomes. Further studies are warranted to identify subsets of
patients who are likely to develop CMV infection and to
determine the impact of antiviral agents on clinically meaningful
outcomes in these patients.
Introduction
Cytomegalovirus (CMV) is a major  herpes virus and a signif-
icant human pathogen. Infection is common with seropreva-
lence rates increasing steadily from 65% among 40 to 49 year
olds to 91% in those aged 80 years or over [1]. After primary
infection, CMV, like other  herpes viruses, establishes life-
long latency. In immunocompetent individuals, asymptomatic
viral shedding may be detectable in saliva or urine; however,
cell-mediated host immune responses prevent the develop-
ment of overt CMV disease.
In contrast, CMV infection has been shown to lead to signifi-
cant disease in immunocompromised hosts such as those
with HIV infection or transplant recipients. End-stage HIV-
infected patients with a CD4 lymphocyte count of less than 50
cells/mm3 are at the highest risk of developing CMV retinitis
[2]. In transplant recipients, CMV disease occurs in 11 to 72%
of patients especially in the first three months after transplant
while the patients are receiving maximum immunosuppression
[3]. In addition to febrile syndrome and end-organ disease
directly as a result of viral replication, immunomodulatory char-
acteristics of CMV may contribute to opportunistic infections,
allograft rejection, and higher mortality in transplant recipients.
Clinical trials have shown that preventive approaches utilizing
antiviral agents have lead to a reduction in the rates of CMV
infection and disease, and indirect sequelae associated with
CMV [3-5]. Currently, prophylaxis or periodic monitoring and
antiviral therapy targeted towards patients with viral replication
are routinely employed at many transplant centers.
APACHE: Acute Physiology and Chronic Health Evaluation; ARDS: acute respiratory distress syndrome; BAL: bronchoalveolar lavage; CI: confidence 
interval; CMV: cytomegalovirus; HHV: human herpesvirus; HSV: herpes simplex virus; ICU: intensive care unit; IL: interleukin; MeSH: medical subject 
headings; NF-B: nuclear factor-B; OR: odds ratio; PCR: polymerase chain reaction; SAPS: simplified acute physiology score; SOFA: sepsis-related 
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It has increasingly come to be recognized that critically ill
patients who are traditionally considered immunocompetent
may also be at risk for CMV infection. For example, septic
insult as a result of bacterial or fungal infections has the poten-
tial to promote the release of immunomodulatory cytokines
and lead to reactivation of CMV [6,7]. Reactivation from the
latency rather than primary infection is believed to be the
cause of CMV infection because none of the critically ill CMV
seronegative patients developed CMV infection as opposed
to 13 to 56% of seropositive patients [8,9]. Several observa-
tional studies have shown an association between CMV infec-
tion in critically ill patients and poor clinical outcomes
[8,10,11]. However, available data are limited by relatively
small sample sizes, diversity in patient populations studied, dif-
ference in methodological assays employed for CMV, and var-
iability in reported outcomes that preclude generalizability of
the results of the individual reports. The objectives of this
review are to summarize the frequency and predictors of CMV
infection, and outcomes in critically ill immunocompetent
patients with CMV infection. Additionally, we discuss the
pathophysiologic basis of CMV reactivation and the implica-
tions of these data for optimizing outcomes in critically ill
patients.
Materials and methods
English-language reports of published studies on CMV infec-
tion in critically ill immunocompetent patients were identified
through November 2008 by cross-referencing the following
medical subject headings (MeSH) keywords and text words:
cytomegalovirus, immunocompetence, critical illness, inten-
sive care units, intensive care, reactivation, sepsis, and shock.
Databases searched included PubMed, EMBASE, Cochrane
Database of Systematic Reviews, and Cochrane Central Reg-
ister of Controlled Trials. Bibliographies of original articles
were manually reviewed for additional articles. Non-English-
language reports were also identified in PubMed using the
same keywords in order to supplement our search.
We included studies in which: critically ill immunocompetent
adults were monitored either retrospectively or prospectively
for the development of CMV infection in the ICU and; the rate
of CMV infection was explicitly reported. CMV infection was
defined as evidence of positive viral cultures, antigenemia,
and/or DNAemia by PCR from blood or a clinical specimen.
Patients were considered to be immunocompetent if they
were not solid organ or hematopoietic stem cell transplant
recipients, not infected with HIV, did not have primary immun-
odeficiencies, and were not recipients of immunosuppressive
agents such as calcineurin-inhibitors, anti-TNF- drugs, anti-
lymphocyte antibodies, or chemotherapeutic agents for treat-
ing cancer. We excluded studies in which an increase in CMV
serologic titers in the absence of viremia was the sole evi-
dence for CMV infection.
Two of the authors independently searched articles and
extracted the following data for analyses: study design, inclu-
sion criteria, type and frequency of CMV assays, rate of CMV
infection, rate of CMV IgG positivity, the time elapsed from
ICU admission to CMV infection, risk factors for CMV infec-
tion, and outcomes (i.e. mortality, duration of ICU stay). Any
discrepancies were resolved by review and discussion.
Authors of published studies were contacted if reported data
required further clarification. Additional mortality data was pro-
vided in one study [12].
Results
Study characteristics
The initial database search identified 524 English-language
and 77 non-English-language studies. After review of the title
and abstract and manual search for bibliographies of the
potentially relevant articles, 26 studies were selected for full-
text review [6-31]. Ten studies were excluded after full-text
review because: CMV infection was diagnosed based on an
increase in titers [19-24]; the study was not explicitly con-
ducted in the ICU [25]; or the rate of CMV infection was not
reported [26,27]. Data from one institution with overlapping
study cohorts in two articles were analyzed only once to avoid
duplication in the results [16,28]. We found three studies in
which CMV disease was sought as etiology of acute respira-
tory distress syndrome (ARDS) or ventilator-associated pneu-
monia (VAP) [29-31]. Considering that CMV disease (organ-
specific symptoms or signs plus the detection of CMV in organ
biopsy samples by histopathology) is a distinct entity with
worse outcomes than CMV infection, the data from these stud-
ies were summarized separately.
Thus, we identified a total of 13 studies that have described
CMV infection in immunocompetent critically ill patients with
sample sizes ranging from 23 to 237 (Table 1) [6-18]. These
included nine prospective observational studies [7,8,10-16],
three retrospective studies [9,17,18], and one study where
insufficient details were available to determine the type of the
study [6]. CMV IgG was positive in all the subjects in four stud-
ies [10,11,14,16], not measured in four studies
[12,15,17,18], and positive in 28 to 94% of the subjects in five
studies [6-9,13]. Other inclusion criteria were sepsis in four
studies [6,7,16,17], mediastinitis in one study [13], simplified
acute physiology score (SAPS) II of 41 or higher in one study
[10], prolonged ICU stay in three studies [8,9,16], fever for
more than 72 hours in one study [18], and shock or organ fail-
ure in two studies [12,16]. There were five studies in which
corticosteroid use was documented [8,12,16-18]. In one
study, eight of 48 patients were recipients of long-term corti-
costeroid therapy or had a malignancy [12]. In a case-control
study, 22 of 40 of the cases and 13 of 40 of the controls were
recipients of short-term corticosteroids ( 3 months) [18]. The
details of corticosteroid use were unavailable in three studies
[8,16,17].Available online http://ccforum.com/content/13/3/R68
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Table 1
Characteristics of studies assessing the rate and outcome of cytomegalovirus infection in critically ill patients
CMV infection Outcome CMV positive vs. 
negative
Study Inclusion 
criteria
Number of 
patients
CMV IgGa Frequency of 
monitoring
Assay 
(specimen)
Ratea Time to 
positivity, 
dayb
Mortality, 
death/total 
(%)
ICU stay, 
dayb
[13] ICU, 
mediastinitis 
after cardiac 
surgery
115 22/78 (28) Every 3 
weeks
Culture 
(blood, 
urine)
29/115 (25) 37 ± 22c 16/29 (55) 
vs. 31/86 
(36) (NS)
69 ± 36 vs. 
48 ± 27 (P 
< 0.05)
Culture 
(blood)
23/115 (20)
[6] ICU, sepsis 60 33/44 (75) Once Culture, 
antigenemia, 
PCR (blood)
43/44 (98) ND ND ND
[14] ICU, 
mechanical 
ventilation
23 23/23 (100) Randomd PCR, culture 
(blood)
0/23 (0) NA NA NA
Randome PCR, culture 
(BAL)
0/14 (0)
[17]f SICU, 
postoperativ
e sepsis with 
no 
identifiable 
sources
142 ND Once, day 
30 ± 5g
Culture 
(blood, 
sputum, 
BAL)
12/142 (8.5) NA 8/12 (66) vs. 
45/130 (35)
ND
[7] ICU, sepsis 34 31/33 (94) Twice 
weekly
PCR (blood) 11/34 (32) 4 (1–23) 7/11 (64) vs. 
17/23 (74) 
(NS)
ND
Antigenemia 6/34 (18) 11 (1–23)
[12] ICU,  2 
organ 
failures
48 ND Once, day 
1.8 ± 2.2b
PCR (blood) 1/48 (2.1) NA 1/1 (100) vs. 
15/47 (32) 
(NS)
ND
Antigenemia 0/48 (0)
[10] ICU, SAPS II 
 41
56 56/56 (100) Every week PCR (blood, 
LRT 
secretions)
20/56 (36) 11 11/20 (55) 
vs. 13/36 
(36) (NS)
30 vs. 23 (P 
= 0.0375)
PCR (blood) 18/56 (32)
Culture (LRT 
secretions)
7/56 (13)
Culture 
(blood)
0/56 (0)
[15] ICU 120 ND Once, day 4 PCR (blood) 1/120 (0.8) NA ND ND
[8] SICU stay  
5 days
104 76/104 (73) Every week Culture 
(blood, LRT 
secretions)
10/104 (10) 28 ± 4g 5/10 (50) vs. 
25/94 (27) 
(NS)
41 vs. 19 (P 
= 0.001)
Culture 
(blood)
6/104 (5.8)
[18] ICU, fever > 
72 hours 
without 
evidence of 
bacteriologic 
or fungal 
origin
237 ND Clinical 
judgment
Antigenemia 40/237 (17) 20 ± 12 20/40 (50) 
vs. 11/40 
(28) (P = 
0.02)
41 ± 28 vs. 
31 ± 22 (P 
= 0.04)Critical Care    Vol 13 No 3    Osawa and Singh 
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Rate of CMV infection
Based on nine prospective studies that assessed CMV infec-
tion in all study subjects, the rate of CMV infection ranged from
0 to 36% with the median rate of 25% [7,8,10-16]. The spec-
imens used to assess CMV infection included blood, urine,
and respiratory secretions. All the studies used blood to
assess CMV infection. Blood was used solely in four studies
[7,11,12,15], whereas urine and respiratory specimen in addi-
tion to blood samples were used in two [13,16] and four stud-
ies [8,10,14,16], respectively. The rate of CMV infection was
reported separately based on the type of specimens in these
studies (Table 1). Considering only studies that assessed for
viremia, the CMV infection rate ranged from 0 to 33% with the
median rate of 20%. Thereafter, we reported the rate of CMV
infection diagnosed based on the presence of viremia.
Next, studies were categorized based on the frequency of viro-
logic monitoring because it can influence the rate of CMV
infection. In five studies in which CMV infection was monitored
at least weekly, the rate of CMV infection ranged from 6 to
33% with the median of 32% [7,8,10,11,16]. In contrast, CMV
infection rate was 0.8 to 2.1% in two studies in which assess-
ment for CMV infection was performed only once, 1.8 to 4
days after ICU admission [12,15].
There are three methods of diagnosing CMV infection: viral
cultures, antigenemia, and PCR assays [32]. Culture-based
assays (conventional and shell-vial cultures) are considered
obsolete because of their low sensitivity and time-consuming
nature. The antigenemia assay is based on direct detection of
the CMV protein pp65 using monoclonal antibodies. It is sen-
sitive and quantitative, although it requires sufficient leuko-
cytes in peripheral blood and is more labor-intensive than the
PCR assays. Finally, the PCR assays have been considered
gold standard given their high sensitivity and rapid turnover
time, although these are not fully standardized [33]. In our
review, the assays used to assess CMV infection were viral
cultures in five studies [8,10,13,14,16], antigenemia in three
studies [7,12,16], and PCR in six studies [7,10-12,14,15].
CMV infection rate was 0 to 20% (median 4%), 0 to 32%
[16] ICU stay  7 
days, septic 
shock
25 25/25 (100) Twice 
weekly in 
week 1, then 
every week
Antigenemia 8/25 (32) 7 (0–14) 5/8 (63) vs. 
6/17 (35) 
(NS)
42 (16–87) 
vs. 18 (10–
42) (P = 
0.0025)
Culture 
(blood, LRT 
secretions, 
urine)
4/25 (16)
Culture 
(blood)
1/25 (4)
[11] ICUh 120 120/120 
(100)
Three times 
weekly
PCR (blood) 39/120 (33) 12 (3–57) CMV viremia 
at any level 
is associated 
with 
continued 
ICU 
hospitalizatio
n or death at 
day 30 (OR 
5.7, 95% CI 
2.1–15.6)
[9] ICU stay  
14 days
99 41/56 (73) Randomi PCR (blood) 35/99 (35)j 17 ± 15 10/35 (29) 
vs. 7/64 (11) 
(P = 0.048)
33 ± 19 vs. 
22 ± 11 (P 
< 0.001)
BAL = bronchoalveolar lavage; CI = confidence interval; CMV = cytomegalovirus; ICU = intensive care unit; LRT = lower respiratory tract; NA = 
not applicable; ND = no data available; NS = not significant; OR = odds ratio; PCR = polymerase chain reaction; SAPS = simplified acute 
physiologic score; SICU = surgical intensive care unit.
a Data were presented as positive/total (%).
b Data were presented as mean ± standard deviation or median (range) unless otherwise indicated.
c Time was measured after heart surgery.
d Blood was collected at a mean of five days for the first sample and 17 days (range: 6 to 29 days) for the others.
e BAL was performed at a mean of 19 days (range: 1 to 41 days).
f Data were presented as combined outcomes of patients with CMV or herpes simplex virus infection in the original article. Data regarding CMV 
infection were extracted for this review.
g Data were presented as mean ± standard error of mean.
h This included admission to the burn ICU with at least 40% body surface burn or at least 20% body surface burn with inhalation injury, to the 
trauma ICU with in Injury Severity Score > 15 and > 4 unit packed red blood cells within 24 hours, to the medical ICU with suspected or 
documented sepsis, or to the cardiac care ICU with a diagnosis of acute myocardial infarction.
i Blood was collected randomly and was stored for red blood cell cross-matching. The first blood samples were drawn on day 6.6 ± 8.2, and the 
last blood samples were drawn on day 20 ± 16.
j 23 of 41 (56%) CMV seropositive patients developed CMV infection.
Table 1 (Continued)
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(median 18%), and 0 to 33% (median 17%) by viral cultures,
antigenemia, and PCR, respectively in these indices. PCR
assay and antigenemia were performed in all patients in two
studies [7,12]. Twelve of 82 patients developed CMV infec-
tion detected by the PCR assay compared with six of the 82
patients by antigenemia. No cases of CMV infection were
diagnosed solely by antigenemia. Lastly, we focused on three
studies in which the PCR assay was used at least weekly
because this method is currently widely utilized to monitor
CMV infection; the rate of CMV infection was 32 to 33% in
these studies [7,10,11].
Time to onset of CMV infection
Based on five studies where CMV infection was assessed at
least weekly, the mean (or median) time to onset of CMV infec-
tion ranged from 4 to 28 days [7,8,10,11,16]. Among studies
where PCR was used, the mean (or median) time ranged from
4 to 12 days [7,10,11]. A PCR assay seems to help diagnose
CMV infection earlier than the antigenemia assay. In a study
that used both methods for the diagnosis of CMV infection, the
median time between onset of sepsis and CMV infection
determined by PCR and antigenemia were four days (range 1
to 23 days) and 11 days (range 1 to 23 days), respectively [7].
Risk factors for CMV infection
Candidate variables assessed as predictors for CMV infection
varied for different studies and primarily included demographic
and clinical characteristics, and severity of illness markers.
Age did not appear to be a risk factor for CMV infection
[7,8,10,11,13,16,18] and the association between CMV
infection and gender was inconsistent [7,8,10,11,13,16,18].
Other risk factors identified included mechanical ventilation at
admission (odds ratio [OR] 8.5, 95% confidence interval [CI]
1.1 to 66.5 for high-grade CMV viremia, i.e. CMV PCR > 1000
copies/ml) [11], bacterial pneumonia [8], and sepsis (OR
4.62, P = 0.02) [10]. Corticosteroid use was a risk factor in
one study [8]. In a retrospective case-control study where var-
iables used in a multivariate logistic regression model were not
clearly documented, neither corticosteroid use nor sepsis was
a risk factor for CMV infection [18]. Transfusion within 24
hours of admission was associated with high-grade viremia,
i.e. CMV viral load greater than 1000 copies/ml (OR 6.7, 95%
CI 1.1 to 42.7) [11]; however, no association between CMV
infection and transfusion during hospitalization was docu-
mented in two other studies [18]. The mean number of packed
red blood cell transfusion was larger in patients with CMV
infection than in those without it (22.3 units vs. 11.2 units, P =
0.002); however, this difference was not statistically signifi-
cant after controlling for other risk factors [8]. Malignancy was
not associated with CMV infection [9,10,18]. None of the dis-
ease severity scores including Acute Physiology and Chronic
Health Evaluation (APACHE) II score [7,8,11,13], sepsis-
related organ failure assessment (SOFA) score [16], or SAPS
II [10,18] correlated with a risk of CMV infection.
Effect of CMV infection on outcomes
Organ dysfunction
Organ dysfunction was reported in three studies [8,13,18].
One study showed a higher incidence of hepatic dysfunction
(international normalized ratio > 1.5 or total bilirubin > 2.5 mg/
dL) in CMV infection group (70% vs. 36%, P < 0.047) [8]. In
two studies, renal failure was observed more frequently in
those with CMV infection (55 to 58% vs. 32 to 33%, P < 0.05
in each study) [13,18].
ICU stay
Based on six studies where the duration of ICU stay was
assessed, the mean (or median) duration of ICU stay ranged
from 33 to 69 days in patients with CMV infection as com-
pared with 22 to 48 days among those without (P < 0.05 in
each study) [8-10,13,16,18].
Mechanical ventilation
The mean (or median) duration of mechanical ventilation
ranged from 21 to 39 days in patients with CMV infection
compared with 13 to 24 days in those without CMV infection
in four studies (P < 0.05 in each study) [8,9,16,18].
Bacterial or fungal infection
Nosocomial infection was more frequently observed in
patients with CMV infection as compared with those without
CMV infection in one study (75% vs. 50%, P = 0.04) [18].
Viral load and outcomes
A higher level of CMV viremia was associated with death or
continued ICU hospitalization at 30 days in one study [11]. An
OR of combined outcome of death or continued ICU hospital-
ization at 30 days was 1.7 (95% CI 1.2 to 2.4) for each loga-
rithmic increase in maximum CMV viral load measured [11].
Mortality
Mortality rate in critically ill patients with CMV infection was 29
to 100% as compared with 11 to 74% in those without CMV
infection. Except for two retrospective studies [9,18], no other
studies showed a significant difference in the mortality rates
between those with and without CMV infection. CMV viremia
at any level was associated with death or continued ICU hos-
pitalization at 30 days (OR 5.7, 95% CI 2.1 to 15.6) [11].
Infections due to other herpes viruses
Human herpesvirus (HHV) -6 and -7 have been associated
with a greater risk of developing CMV disease in transplant
recipients [34-37]. Furthermore, HHV-6 and HHV-7 have
been shown to be significant contributors to morbidity and
poor outcomes, particularly when concurrent infection with
CMV exists [35,38-40]. Thus, it is of interest to investigate
whether the association between CMV and other herpes
viruses exists in critically ill patients.Critical Care    Vol 13 No 3    Osawa and Singh 
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Human herpesviruses -6 and -7
HHV-6 infection has been frequently observed in critically ill
patients [12,15]. In one study, HHV-6 infection occurred in
53.5% of all patients (54/101) requiring hospitalization in the
ICU as compared with none of the healthy volunteers [15]. In
another study, HHV-6 infection occurred in 54% of all ICU
patients with at least two organ failures as opposed to 15% of
those with less than two organ failures [12]. HHV-6 viremia
was assessed by the PCR assay at a mean of day 4 and day
1.8, respectively [12,15]. Potential association between CMV
and HHV-6 infection could not be assessed because only one
patient developed CMV infection in each study. Both studies
failed to show an association between HHV-6 infection and
mortality. HHV-7 infection was observed more commonly in
healthy volunteers (18/50, 36%) as compared with ICU
patients (14/101, 14%; P = 0.002) in one study [15].
Herpes simplex virus
Three studies evaluated herpes simplex virus (HSV) infection
in conjunction with CMV infection. In one study, HSV was iso-
lated in the bronchial aspirate of 8 of 25 patients (32%) con-
sisting of six of eight patients with CMV reactivation and 2 of
17 patients without CMV infection (P = 0.004) [16]. In other
studies, none or only one patient developed co-infection of
CMV and HSV, therefore, the association between CMV and
HSV could not be evaluated [8,17].
CMV disease and acute respiratory distress syndrome or 
ventilator-associated pneumonia
CMV pneumonia was diagnosed by open-lung biopsy while
investigating the etiology of pulmonary disease in 29 to 50%
of critically ill patients with ARDS or VAP (Table 2) [29-31]. In
a study in which open-lung biopsy led to the diagnosis of CMV
pneumonia in 30% of critically ill patients with ARDS, lung tis-
sue culture was positive only in 10% of these patients [29].
The sensitivity/specificity of bronchoalveolar lavage (BAL),
blood, and urine culture for the diagnosis of histologically
proven ventilator-associated CMV pneumonia was 53%/92%,
20%/83%, and 13%/62%, respectively [31]. Clinical out-
come data were largely lacking; however, there was no differ-
ence in duration of ICU stay in one study [31].
Discussion
Our review demonstrates that depending on the methodolog-
ical assay used and the patient populations studied, CMV
infection occurs in 0 to 36% of the critically ill otherwise immu-
nocompetent hosts in the ICU. Among the most frequently
studied inciting event for CMV infection in these patients is
sepsis [6,7,13,16,17]. The risk of CMV infection was five-fold
higher in patients with sepsis even when controlled for age
and the initial severity of illness [10]. In a murine model of CMV
infection, cecal ligation and puncture resembling post-surgical
intraabdominal sepsis led to reactivation of latent CMV in the
lungs and ultimately pulmonary fibrosis [41,42]. The propen-
sity of sepsis to promote CMV infection may result from its
pleiotropic effects on the host immune system. Pro-inflamma-
tory cytokine production such as TNF- and IL-1 in the early
phase of sepsis has the potential to activate NF-B and other
transcription factors that are key in the reactivation of CMV
from latency [43,44]. The later phase of sepsis, characterized
by the generation of immunosuppressive cytokines such as IL-
10 and IL-4 is often referred to as compensatory anti-inflam-
matory response syndrome [45,46]. Once latent virus is reac-
tivated, these cytokines may further enhance CMV replication.
Indeed, in lung transplant recipients, elevated levels of IL-10 in
the BAL and/or plasma were associated with delayed CMV
clearance [47]. A sustained high level of IL-10 in patients with
sepsis has been associated with poor outcomes, presumably
due to excessive anti-inflammatory effects [48].
Transfusion within 24 hours of admission was identified as a
risk factor for high-grade CMV viremia in critically ill patients
[11]. This association may be explained by potential transmis-
sion of CMV by blood products, but more likely by the immu-
nomodulatory effect of transfusion per se. Previous studies
have shown that allogeneic blood transfusion resulted in a
reduction in T-helper cells, induction of suppressor T cells, and
suppression of natural killer cell activity [49]. The transfusion-
related immunosuppression has been associated with clini-
cally important sequelae such as improvement of renal allo-
graft survival, increased risk of tumor recurrence, and
postoperative infections [50-52]. The risk of CMV transmis-
sion by leukocyte depleted blood products is at least as low as
by CMV seronegative blood products [53,54], supporting the
hypothesis that transfusion-related immunomodulatory effect
plays a major role in CMV infection in critically ill patients if
transfusion were truly a risk factor. However, these data were
not available for most studies. For example, only one in three
studies that evaluated transfusion as potential risk factors for
CMV infection reported use of leukocyte depleted blood prod-
ucts explicitly [18].
A body of literature based largely on serologic assays for the
diagnosis of CMV suggests that severe burn injuries are a
major risk factor for CMV infection [55,56]. At least a four-fold
rise in serologic titers suggestive of CMV reactivation has
been documented in 45 to 56% of the burn patients
[19,21,22]. Recently, in a study where patients with severe
burn injuries comprised a subset of critically ill patients, CMV
viremia using PCR was observed in 55% (11/20) of the burn
patients [11]. Burn injuries are associated with profound
changes in cell-mediated immunity and a predominant T-
helper 1 cell response that may facilitate CMV infection [57-
59]. Susceptibility to sepsis due to the loss of skin integrity in
these patients may also contribute to the risk of CMV infection.
Attempts to utilize the severity of 'critical illness' to predict
CMV infection have not shown a correlation between scoring
systems such as APACHE II or SAPS II and the risk of CMV
[7,8,10,11,13,16,18]. Severity of illness scores have typicallyAvailable online http://ccforum.com/content/13/3/R68
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been assessed in the first 24 hours after ICU admission
whereas CMV infection does not usually occur until late in the
ICU stay. Additionally, these scores are based on age, physio-
logic parameters, basic laboratory values, and chronic medical
conditions and may not be necessarily representative of host
immunologic deficits that lead to CMV infection.
CMV infection rate was 0.8 to 2.1% in two studies where the
PCR assay was performed only once at a mean of 1.8 and 4
days following the onset of illness requiring ICU admission
[12,15]. The median time to first detectable CMV viremia was
12 days (range 3 to 57 days) in a study where the PCR assay
was performed thrice weekly [11]. Thus, it appears that CMV
infection is a rare event very early in the course of critically ill
patients and that most infections develop between 4 and 12
days after the onset of illness requiring ICU stay, which could
lead to a hypothesis that CMV infection may coincide with the
development of compensatory anti-inflammatory response
syndrome, and not with the initial surge of pro-inflammatory
cytokines.
A key question is whether CMV infection adversely affects out-
comes in critically ill patients. Virtually all studies have docu-
mented that CMV infection was related to prolonged
mechanical ventilation and duration of ICU stay in patients with
CMV infection. CMV infection has also been associated with
organ system failure and at least two studies have docu-
mented significantly higher mortality rates in patients with
CMV infection compared with those without it [9,18]. Thus,
although these data do not prove a causal association as CMV
infection may have been more likely to develop or diagnosed
in sicker patients, existing evidence suggests that CMV infec-
tion is associated with poor outcomes even in immunocompe-
tent critically ill patients. We believe that a causal association
between these can only be assessed by carefully conducted
clinical trials designed to show whether suppression of CMV
has a mitigating effect on the severity of illness.
Another major unresolved issue is whether CMV infection is
associated with overt disease or clinical manifestations
directly attributable to this virus in critically ill patients. CMV
infection in immunocompetent patients generally presents
with mononucleosis-like symptoms including fever and
malaise with liver enzyme abnormalities [60,61], which are typ-
ically benign. However, 31 to 42% of the hospitalized patients
with CMV infection may have organ involvement [60,62] and
rarely life-threatening CMV infection has also been reported
[63,64]. In critically ill patients, 10% (2/20) of those with CMV
infection eventually developed severe CMV disease (pneumo-
nitis, neurologic disease) in one study [10]. CMV pneumonia
has also been diagnosed in 29 to 50% of patients with ARDS
or VAP [29-31]; however, this does not necessarily mean that
CMV is the cause of ARDS or VAP. Critical illness due to seri-
ous pulmonary disease may predispose these patients to CMV
infection in the lungs. In a cohort study in the ICU, 17% of crit-
ically ill patients who experienced fever for three or more days
had CMV infection [18]. Current guidelines for the evaluation
of new fever in critically ill adult patients list transfusion-asso-
Table 2
Characteristics of studies assessing the rate of cytomegalovirus pneumonia in critically ill patients
CMV infection Outcome CMV positive vs. 
negative
Study Inclusion criteria Number of 
patients
CMV IgGa Time of 
histologic 
examination, day
Methods Ratea Mortality, 
death/total (%)
ICU stay
[31] ICU, acute 
respiratory failure 
or VAP, negative 
BAL cultures
86 13/18 (72) 18 (10–40)b Autopsy or 
open-lung 
biopsy
25/86 (29) ND No difference
[30] ICU,  5 days of 
evolution of ARDS, 
negative 
microbiological 
cultures
36 ND 10 (5–55)c Open-lung 
biopsy
18/36 (50) ND ND
[29] ICU,  5 days of 
evolution of ARDS, 
negative 
microbiological 
cultures
100d ND 7 (6–13.5)c Open-lung 
biopsy
30/100 (30) ND ND
Lung tissue 
culture
10/100 (10)
ARDS = acute respiratory distress syndrome; BAL = bronchoalveolar lavage; CMV = cytomegalovirus; ICU = intensive care unit; NA = not 
applicable; ND = no data available; VAP = ventilator-associated pneumonia.
a Data were presented as positive/total (%).
b Time was measured after the ICU admission.
c Time was measured after the onset of ARDS.
d Four immunocompromised patients were included.Critical Care    Vol 13 No 3    Osawa and Singh 
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ciated CMV mononucleosis as a cause of fever [65]. However,
it remains to be determined whether and how often CMV pro-
duces febrile syndrome and whether coexistent infection with
HHV-6 is a contributor to this entity as shown in the transplant
setting [34,36-40].
Experimental studies have shown that ganciclovir prevented
murine CMV reactivation and the development of pulmonary
fibrosis in immunocompetent mice with sepsis [42]. Two ret-
rospective studies where small subsets of ICU patients
received antiviral agents for CMV infection have yielded incon-
clusive results and data on the utility and efficacy of antiviral
therapy for CMV in critically ill immunocompetent patients are
largely lacking [17,18]. Employment of potent antiviral therapy
in all critically ill patients may be impractical, logistically infea-
sible, and potentially harmful given a large number of ICU
patients and potential adverse effects of ganciclovir such as
bone marrow suppression or teratogenicity. A more prudent
approach may be to identify subgroups of patients at high risk
for developing CMV infection and targeting antiviral prophy-
laxis towards these patients. These subgroups may include
patients with sepsis, persistent fever, or those receiving trans-
fusion. An alternative approach is to employ antiviral therapy
only in those with CMV viremia. Regardless, carefully con-
ducted clinical trials are warranted to discern the impact of
antiviral agents on clinically meaningful outcomes before
employing antiviral therapy or even considering routine moni-
toring of CMV in critically ill patients.
Several limitations of our study deserve to be acknowledged.
We found considerable heterogeneity in the methodology
used to assess CMV infection and in patient characteristics.
As noted in the Results, the frequency and type of CMV mon-
itoring influenced the rate of CMV infection. Although all the
studies in this review were conducted in the ICU, the overall
mortality of the studied patients ranged from 5 to 71% [7,15],
suggesting that study populations were significantly diverse.
Furthermore, these studies were published over a period
spanning nearly two decades in different regions with diverse
clinical practices. Considering the heterogeneity of available
data, quantitative analyses such as meta-analysis can be mis-
leading [66,67] and our results are therefore presented in a
descriptive fashion only. Second, while we excluded the recip-
ients of iatrogenic immunosuppressive agents that enhance
the risk of CMV reactivation, critically ill patients in whom cor-
ticosteroids were employed were included. Controversy
abounds whether corticosteroids alone without other immuno-
suppressive agents lead to reactivation of CMV from latency
or merely promote the replication of activated virus [68-70].
Corticosteroids were employed in a subset of patients in 5 of
12 studies in this review. Given that corticosteroid use is a
common practice in the ICU [71], these studies reflect clinical
scenarios encountered by care providers and therefore their
inclusion in this review was deemed appropriate.
Conclusions
In summary, accumulating data suggest that CMV infection is
a frequent occurrence in critically ill patients. Considering a
large number of patients requiring ICU level of care, the scope
of impact of CMV infection in these patients may be equally or
potentially wider than in other immunocompromised hosts tra-
ditionally recognized to be at risk for CMV infection. For exam-
ple in the USA, an estimated 383,000 cases with sepsis
require ICU admission as opposed to 28,360 solid organ
transplant cases yearly [72,73]. Mortality rate in patients with
sepsis ranges from 20 to 50% and approaches 70% in those
with multiple organ failure [74]. Furthermore, the incidence of
sepsis and the number of sepsis-related deaths appear to be
increasing [73,74]. Precise identification of the role of CMV as
a contributor to outcomes in these patients may therefore have
far reaching implications. Subsets of critically ill patients who
are at risk for developing CMV infection and for poor out-
comes remains to be determined. These studies have signifi-
cant implications for future investigations to determine the
potential benefits and for guiding the study design to evaluate
the impact of antiviral agents on clinically meaningful out-
comes in critically ill patients.
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